Pharmacology for Nurses
Pharmacology for Nurses
A Pathophysiologic Approach

Michael Patrick Adams
Adjunct Professor of Anatomy and Physiology
Hillsborough Community College
Formerly Dean of Health Professions
Pasco-Hernando State College

Leland Norman Holland, Jr.
Professor
Hillsborough Community College
Polk State College

Carol Quam Urban
Associate Dean for Practice and Strategic Initiatives
Associate Professor
College of Health and Human Services
George Mason University

Pearson
About the Authors

MICHAEL PATRICK ADAMS, PHD, is an accomplished educator, author, and national speaker. The National Institute for Staff and Organizational Development in Austin, Texas, named Dr. Adams a Master Teacher. He has published two other textbooks with Pearson Publishing: Core Concepts in Pharmacology and Pharmacology: Connections to Nursing Practice.

Dr. Adams obtained his master’s degree in pharmacology from Michigan State University and his doctorate in education from the University of South Florida. Dr. Adams was on the faculty of Lansing Community College and St. Petersburg College, and served as Dean of Health Professions at Pasco-Hernando State College for 15 years. He is currently Adjunct Professor of Biological Sciences at Hillsborough Community College.

I dedicate this book to nursing educators, who contribute every day to making the world a better and more caring place.

—MPA

LELAND NORMAN HOLLAND, JR., PHD (NORM), over 25 years ago, started out like many scientists, planning for a career in basic science research. He was quickly drawn to the field of teaching in higher medical education, where he has spent most of his career. Among the areas where he has been particularly effective are preparatory programs in nursing, medicine, dentistry, pharmacy, and allied health. Dr. Holland is both a professor and supporter in nursing education nationwide. He brings to the profession a depth of knowledge in biology, chemistry, and medically related subjects, such as microbiology, biological chemistry, and pharmacology. Dr. Holland’s doctoral degree is in medical pharmacology. He is very much dedicated to the success of students and their preparation for careers in health care. He continues to motivate students in the lifelong pursuit of learning.

To the greatest family in the world: Karen, Alexandria, Caleb, and Joshua.

—LNHII

CAROL QUAM URBAN, PHD, RN, Associate Professor, is the Associate Dean for Practice and Strategic Initiatives in the College of Health and Human Services at George Mason University in Fairfax, Virginia. Teaching in the School of Nursing for over 25 years, and most recently in the position of Director of the School, she considers pharmacology to be a course that truly integrates nursing knowledge, skills, and interdisciplinary teamwork. She has co-authored the Pearson textbook Pharmacology: Connections to Nursing Practice with Dr. Adams.

To my daughter, Joy, an extraordinary pediatric hematology-oncology nurse, and in memory of my son, Keith, and husband, Michael.

—CQU
Thank You

Our heartfelt thanks go out to our colleagues from schools of nursing across the country who have given their time generously to help create this exciting new edition. These individuals helped us plan and shape our book and resources by reviewing chapters, art, design, and more. Pharmacology for Nurses: A Pathophysiologic Approach, sixth edition, has reaped the benefit of your collective knowledge and experience as nurses and teachers, and we have improved the materials due to your efforts, suggestions, objections, endorsements, and inspiration. Among those who gave their time generously are the following:

Beatrice Adams, PharmD
Critical Care Clinical Pharmacist
Tampa General Hospital
Department of Pharmacy
Tampa, Florida

Shannon Allen, CRNA, MSNA
Professor
New Mexico Junior College
Hobbs, New Mexico

Candice Antley, RN, MN
Instructor
Midlands Technical College
Columbia, South Carolina

Culeta Armstrong, MSN, RN
Clinical Assistant Professor
University of Memphis
Memphis, Tennessee

Wanda Barlow, MSN, RN, FNP-BC
Instructor
Winston-Salem State University
Winston-Salem, North Carolina

Sophia Beydoun, RN, BSN, MSN, AA-AND
Professor
Henry Ford Community College
Dearborn, Michigan

Staci Boruff, PhD, RN
Assistant Academic Dean of Health Programs
Professor of Nursing
Walters State Community College
Morristown, Tennessee

Bridget Bradley, PharmD, BCPP
Assistant Professor
Pacific University
Hillsboro, Oregon

Mary M. Bridgeman, PharmD, BCPP, CGP
Clinical Assistant Professor
Rutgers University
Piscataway, New Jersey

Reamer L. Bushardt, PharmD, P.A.-C
Professor
Wake Forest Baptist Health
Winston-Salem, North Carolina

Marcus W. Campbell, PharmD, BC-ADM
Assistant Professor Pharmacy Practice
Director, Center for Drug Information & Research
LECOM School of Pharmacy
Bradenton, Florida

Rachel Choudhury, MSN, MS, RN, CNE
Associate Dean and Program Director, ABSN
Musco School of Nursing and Health Professions
Grandman University
Irving, California

Darlene Clark, MS, RN
Senior Lecturer in Nursing
Pennsylvania State University
University Park, Pennsylvania

Janice DiFalco, RN, MSN, CNS, CMSRN, FAACVPR
Professor
San Jacinto College
Pasadena, Texas

Deepali Dixit, PharmD, BCPS
Clinical Assistant Professor
Rutgers University
Piscataway, New Jersey

Rachael Durie, PharmD, BCPS
Cardiology Clinical Pharmacist
Assistant Professor of Clinical Pharmacy
Rutgers University
Neptune, New Jersey

Deborah Dye, RN, MSN
Assistant Professor/Nursing Department Chair
Ivy Tech Community College
Lafayette, Indiana

Jacqueline Frock, RN, MSN
Professor of Nursing
Oklahoma City Community College
Oklahoma City, Oklahoma

Jasmine D. Gonzalvo, PharmD, BCPS, BC-ADM, CDE
Clinical Associate Professor
Purdue University
West Lafayette, Indiana

Adina C. Hirsch, PharmD, BCNSP
Assistant Professor of Pharmacy Practice
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

Linda Howe, PhD, RN, CNS, CNE
Associate Professor
University of Central Florida
Orlando, Florida

Anne L. Hume, PharmD, FCCP, BCPS
Professor of Pharmacy
University of Rhode Island
Kingston, Rhode Island

Ragan Johnson, DNP, APRN-BC
Assistant Professor
University of Tennessee
Memphis, Tennessee

Vinh Kieu, PharmD
Assistant Professor
George Mason University
Fairfax, Virginia

Dorothy Lee, PhD, RN, ANP-BC
Associate Professor of Nursing
Saginaw Valley State University
University Center, Michigan

Toby Ann Nishikawa, MSN, RN
Assistant Professor
Weber State University
Ogden, Utah

Dr. Diana Rangaves, PharmD, RPh
Director, Pharmacy Technology Program
Santa Rosa Junior College
Santa Rosa, California

Timothy Reilly, PharmD, BCPS, CGP, FASCP
Clinical Assistant Professor
Rutgers University
Piscataway, New Jersey

Janet Czermak Russell, MS, MA, APN-BC
Associate Professor
Essex County College
Newark, New Jersey
Pooja Shah, PharmD  
Clinical Assistant Professor  
Rutgers University  
Piscataway, New Jersey

Samantha Smeltzer, RN  
Professor of Nursing  
Mount Aloysius College  
Cresson, Pennsylvania

Rose Marie Smith, RN, MS, CNE  
Division Dean of Nursing, Liberal  
Arts, Social and Behavioral  
Sciences  
Redlands Community College  
El Reno, Oklahoma

Dustin Spencer, DNP, NP-C, ENP-BC  
Assistant Professor of Nursing  
Saginaw Valley State University  
University Center, Michigan

Dr. Jacqueline Stewart, DNP, CEN,  
CCRN  
Associate Professor of Nursing  
Wilkes University  
Wilkes-Barre, Pennsylvania

Rebecca E. Sutter, DNP, APRN,  
FNP-BC  
Associate Professor  
George Mason University  
Fairfax, Virginia

Suzanne Tang, MSN, APRN, FNP-BC  
Instructor  
Rio Hondo College  
Whittier, California

Ryan Wargo, PharmD, BCACP  
Assistant Professor of Pharmacy  
Practice  
Director of Admissions  
LECOM School of Pharmacy  
Bradenton, Florida

Timothy Voytilla, MSN, ARNP  
Nursing Program Director  
Keiser University  
Tampa, Florida
Preface

When students are asked which subject in their nursing program is the most challenging, pharmacology always appears near the top of the list. The study of pharmacology demands that students apply knowledge from a wide variety of the natural and applied sciences. Successfully predicting drug action requires a thorough knowledge of anatomy, physiology, chemistry, and pathology as well as the social sciences of psychology and sociology. Lack of adequate pharmacology knowledge can result in immediate and direct harm to the patient; thus, the stakes in learning the subject are high.

Pharmacology cannot be made easy, but it can be made understandable when the proper connections are made to knowledge learned in these other disciplines. The vast majority of drugs in clinical practice are prescribed for specific diseases, yet many pharmacology textbooks fail to recognize the complex interrelationships between pharmacology and pathophysiology. When drugs are learned in isolation from their associated diseases or conditions, students have difficulty connecting pharmacotherapy to therapeutic goals and patient wellness. The pathophysiology focus of this textbook gives the student a clearer picture of the importance of pharmacology to disease and, ultimately, to patient care. The approach and rationale of this textbook focus on a holistic perspective to patient care which clearly shows the benefits and limitations of pharmacotherapy in curing or preventing illness. In addition to its pathophysiology focus, medication safety and interdisciplinary teamwork are consistently emphasized throughout the text. Although difficult and challenging, the study of pharmacology is truly a fascinating, lifelong journey.

New to This Edition

The sixth edition of Pharmacology for Nurses: A Pathophysiologic Approach has been thoroughly updated to reflect current pharmacotherapeutics and advances in understanding disease.

- NEW! Applying Research to Nursing Practice feature illustrates how current medical research is used to improve patient teaching. Books, journals, or websites may be cited, and the complete source information provided in the References section at the end of the chapter.
- NEW! Key terms are listed at the beginning of each chapter along with corresponding page numbers that indicate where their definitions may be found within the chapter.
- UPDATED! Check Your Understanding questions appear throughout the drug chapters to reinforce student knowledge.
- EXPANDED! Includes more than 40 new drugs, drug classes, indications, and therapies that have been approved since the last edition.
- UPDATED! Black Box Warnings issued by the FDA are included for all appropriate drug prototypes.
- UPDATED! Pharmacotherapy Illustrated diagrams help students visualize the connection between pharmacology and the patient.
- UPDATED! Nursing Practice Application charts have been revised to contain current applications to clinical practice with key lifespan, safety, collaboration, and diversity considerations noted.

Organization and Structure—A Body System and Disease Approach

Pharmacology for Nurses: A Pathophysiologic Approach is organized according to body systems (units) and diseases (chapters). Each chapter provides the complete information on the drug classifications used to treat the diseases. Specially designed numbered headings describe key concepts and cue students to each drug classification discussion.

The pathophysiologic approach clearly places the drugs in context with how they are used therapeutically. The student is able to locate easily all relevant anatomy, physiology, pathology, and pharmacology in the same chapter in which the drugs are discussed. This approach provides the student with a clear view of the connection among pharmacology, pathophysiology, and the nursing care learned in other clinical courses.

The vast number of drugs available in clinical practice is staggering. To facilitate learning, this text uses drug prototypes in which the most representative drugs in each classification are introduced in detail. Students are less intimidated when they can focus their learning on one representative drug in each class.
This text uses several strategies to connect pharmacology to nursing practice. Throughout the text the student will find interesting features, such as Complementary and Alternative Therapies, Treating the Diverse Patient, Community-Oriented Practice, and Lifespan Considerations, that clearly place the drugs in context with their clinical applications. Applying Research to Nursing Practice features illustrate how current medical research is used to improve patient teaching. Patient Safety illustrates potential pitfalls that can lead to medication errors. PharmFacts contain statistics and facts that are relevant to the chapter. Check Your Understanding features encourage students to apply what they have already read in the chapter.

Students learn better when supplied with accurate, attractive graphics and rich media resources. Pharmacology for Nurses: A Pathophysiologic Approach contains a generous number of figures, with an unequaled art program. Pharmacotherapy Illustrated features appear throughout the text, breaking down complex topics into easily understood formats. Animations of drug mechanisms show the student step-by-step how drugs act.

### Prototype Drug

**Valproic Acid (Depakene, others)**

**Pharmacologic Class:** Antiseizure drug

**Actions and Uses**

Valproic acid has become a preferred drug for treating many types of epilepsy. This medication has several trade names and formulations, which can cause confusion when studying it:

- Valproic acid (Depakene) is the standard form of the drug given PO.
- Valproate sodium (Depacon) is the sodium salt of valproic acid given PO or IV.
- Divalproex sodium (Depakote ER) is a sustained release combination of valproic acid and its sodium salt in a 1:1 mixture. It is given PO and is available in an enterico-

All three formulations of the drug form the chemical valproate after absorption or on entering the brain. The pharmacokinetics of each form varies, and doses are not interchangeable. In this text, the name valproic acid is used to describe all forms of the drug, unless specifically stated otherwise.

Valproic acid is administered as monotherapy or in combination with other AEDs to treat absence seizures and complex partial seizures. Divalproex ER is also approved for the prevention of migraine headaches and mets associated with bipolar disorder. Off-label indications include severe behavioral disturbances, such as agitation due to dementia, Alzheimer’s disease, or explosive temper in patients with ADHD, persistent hiccups, and status epilepticus refractory to IV diazepam.

**Administration Alerts**

- Valproic acid is a gastrointestinal (GI) irritant. Advise patients not to chew extended-release tablets because mouth soresness will occur.
- Do not mix valproic acid syrup with carbonated beverages because it will trigger immediate release of the drug, which causes severe mouth and throat irritation.
- Open capsules and sprinkle on soft foods if the patient cannot swallow them.
- Pregnancy category D.

### Complementary and Alternative Therapies

#### THE KETOGENIC DIET FOR EPILEPSY

The ketogenic diet is most often used when seizures cannot be controlled through pharmacotherapy or when there are unacceptable adverse effects to the medications. Before antiseizure drugs were developed, this diet was a primary treatment for epilepsy. Recent studies have examined the possibility that the ketogenic diet could provide benefit for patients with Alzheimer’s, Parkinson’s, and other neurodegenerative diseases (Rajagopal, Sangam, Singh, & Joginapally, 2016; Veyrat-Durex et al., 2018). The exact mechanism behind the effectiveness of the diet is unknown and appears to include both direct effect from ketone body increases, and metabolic changes that occur, increasing GABA and inhibitory neurotransmit-

### Treating the Diverse Patient: Sports-Related Concussions

There is increased awareness and concern about sports-related concussions at all ages. Concussions are a form of traumatic brain injury (TBI) and can range from mild to severe, with immediate and long-term consequences, including dementia and chronic traumatic encephalopathy (Thomas et al., 2018). Ban, Botros, Madden, and Batjer (2016) found a relatively low incidence of sports-related TBI, but an estimated 13% of pediatric, and 14% of adult injuries were considered moderate to severe. While headaches, dizziness, and visual disturbances were common after a mild injury, seizures were more common with severe sports-related concussions, and symptoms may persist and become chronic (Choe et al., 2016; Merritt, Rabinowitz, & Arnett, 2015). Early detection and intervention is a key strategy in the appropriate treatment of a concussion, but not all patients, particularly children, seek treatment. Bryan, Rowhani-Rahbar, Comstock, & Rivera (2016) found that as many as 52% of high school sports and recreation-related concussions were not reported to a health care provider, and the authors recommend expanding research to include recreation-related injuries as a cause of TBI. For children, parents play a key role in identifying and managing these injuries. However, particularly among parents with low income, education is lacking (Lin et al., 2015). Because seizures and long-term complications may occur after a moderate to severe injury, education on prevention and early detection may help to decrease these consequences.
Community-Oriented Practice
PREPARING FOR DISASTERS: THE NURSE’S ROLE

When a disaster strikes, nurses and other healthcare providers may be expected to provide disaster relief, whether or not they have received training in this area. Normal healthcare infrastructure may be severely diminished or absent, and nurses will be relied on to provide care and information and to be able to improvise due to a lack of resources. Ruskie (2016) points out that during such a disaster people and nurses experience the loss of basic needs, such as electricity and water, and a lack of providers, supplies, equipment, and staff. As well, nurses find themselves tending to populations not usually encountered in their usual practice setting, such as the homeless or mentally ill. All of this can cause nurses to experience psychosocial, physical, and emotional distress in ways that could not be anticipated in disaster preparedness drills.

In reviewing the state of current preparedness, Adams, Karlin, Eisenman, Blakeley, and Glick (2017) and Gowing, Walker, Elmer, and Cummings (2017) suggest that community-oriented, interprofessional team approaches will be needed, and they advocate for preparedness and training that goes beyond the current hospital or healthcare-based training programs. Novel approaches to training include using interactive, gaming, or other virtual strategies; involving communities in awareness and training for personal preparedness; and providing training that involves healthcare teams with defined competencies.

Whether the cause is a natural disaster, such as a tornado, an earthquake, or a hurricane, or a disaster caused by accidental causes or terrorism, nurses may be called upon to work very long hours, use whatever supplies they have on hand, make decisions without the benefit of consulting with other healthcare providers, and use the full extent of their education to make decisions about care. Planning ahead, participating in disaster preparedness drills while also expecting reduced or absent resources, working with unfamiliar patient populations, and becoming the resource for a community may be expected of the nurse in a disaster. Expecting the unexpected, but being prepared, is a role that nurses are well trained to fulfill.

Lifespan Considerations
Nonmedical Use of CNS Stimulant Medications

Whether due to improved diagnostic criteria or a true increase, the number of children in the United States diagnosed with ADHD continues to increase (Centers for Disease Control, 2018). As CNS stimulant prescriptions are used to treat the condition, the misuse of the drugs rises. Multiple studies have investigated the nonmedical use of CNS stimulant medications (i.e., the misuse and diversion of the drugs for purposes other than the prescribed condition), and commonalities have emerged.

For children and adolescents, it appears that the earlier a stimulant drug is started, the less the chance for nonmedical use later, suggesting that there is a crucial time in brain and physical development that may increase the risk of misuse when the drugs are started in late childhood or adolescence (McCabe, Veliz, & Boyd, 2016). Among adolescents who used ADHD stimulants inappropriately, it was found that there was often a concurrent substance misuse problem, with alcohol being the most common substance also used (Chen, Crum, Strain, Martins, & Motlaba, 2015; McCabe, Veliz, & Patrick, 2017). Overall, a slight decrease in the use of amphetamine misuse declined in recent years in adolescents (Johnston et al., 2015), but no decline was noted in adults age 21 to 55 (Schulenberg et al., 2017).

Physician prescribing practices also play a role. Colameri, Keim, and Adesman (2017) found that few physicians used medication contracts or distributed drug education literature to their patients.

Being aware of high-risk populations can assist nurses with targeting interventions. “SBIRT” is an evidence-based model to identify and begin treatment for substance misuse (SAMHSA-HRSA Center for Integrated Health Solutions, n.d.). Using the model, Screening, Brief Intervention, and Referral to Treatment begins the process of treatment for substance misuse. Because nurses are often the first healthcare professional the patient encounters, and the one who provides the most health teaching, using the SBIRT model and a thorough drug and social history may aid in determining the patients most in need of additional treatment.

Applying Research to Nursing Practice: New Uses for Ketamine

Ketamine is classified as a general anesthetic that is used for conscious sedation, where a patient is conscious but dissociated from their environment with resultant amnesia. With the concern for opioid misuse, research into additional uses for ketamine is ongoing.

Past studies have demonstrated that ketamine has some effectiveness in treating depression in patients with bipolar disorder and depression in patients with a family history of alcohol use disorder (Nicu et al., 2014; Zarate et al., 2012). More recent studies have shown that ketamine may be useful in the treatment of post-traumatic stress disorder (PTSD), for treatment-resistant depression, and as a treatment for pain (Buwanendran et al., 2018; Hartberg, Garrett-Walcott, & De Gioannis, 2018; Krystal et al., 2017; Schoevers, Chaves, Balukova, Rot, & Korteakaas, 2016). As concern grows over the misuse of opioids, previous studies into the use of nonopioid treatments are being reconsidered.

Ketamine is usually given parenterally, but oral use has also been shown to be effective (Buwanendran et al., 2018; Hartberg, Garrett-Walcott, & De Gioannis, 2018; Schoevers et al., 2016). Specialized treatment centers are also being established touting the use of ketamine for depression, PTSD, obsessive-compulsive disorder, and fibromyalgia, even though published research accounts are in the preliminary stages. The authors acknowledge the need for more research and randomized clinical trials before the drug can be recommended for these disorders. Because patients may inquire about these treatment centers, nurses should know that ketamine is not currently approved for use in these conditions and advise patients to discuss any adjunctive treatment with their healthcare provider.

01/09/2019 22:38
Pharmacotherapy Illustrated 14.1, the regions of the brain affected by antianxiety medications.

### PharmFacts

#### Anxiety Disorders
- An estimated 40 million American adults suffer from anxiety disorders.
- Illnesses that commonly coexist with anxiety include depression, eating disorders, and substance abuse.
- Anxiety disorders affect 25% of children between the ages of 13 and 18.
- Although highly treatable, only about 37% of those having an anxiety disorder receive treatment. (Anxiety and Depression Association of America, n.d.)


---

**Patient Safety: Inappropriate Drug Substitution**

A patient has Tylenol #3 with codeine ordered. When opening the medication dispensing system, the cassette for Tylenol #3 is empty, but Tylenol #2 is available. Consulting a drug guide as needed, why would it be inappropriate for the nurse to give two Tylenol #2 tablets in place of one Tylenol #3? See Appendix A for the answer.

---

**Check Your Understanding 13.1**

A 64-year-old man is taking atenolol (Tenormin) for treatment of hypertension. His seasonal allergies have been worse this year, and he is considering an OTC decongestant, pseudoephedrine (Sudafed), which a friend recommended. Is this medication safe for him to take? See Appendix A for the answer.

---

### Pharmacotherapy Illustrated 26.1 | Mechanism of Action of Antihypertensive Drugs

- **Alpha1 agonists**: Decrease sympathetic impulses from the CNS to the heart and arterioles, causing vasodilation.
- **Alpha2 blockers**: Inhibit sympathetic activation in arterioles, causing vasodilation.
- **Direct vasodilators**: Act on the smooth muscle of arterioles, causing vasodilation.
- **Calcium channel blockers**: Block calcium ion channels in arterial smooth muscle, causing vasodilation.
- **Angiotensin receptor blockers**: Prevent angiotensin II from reaching its receptors, causing vasodilation.
- **ACE inhibitors**: Block formation of angiotensin II, causing vasodilation, and block aldosterone secretion, decreasing fluid volume.

---

One of the strongest components of Pharmacology for Nurses: A Pathophysiologic Approach is the Nursing Practice Application feature. This feature clearly and concisely relates pharmacotherapy to patient assessment, planning patient outcomes, implementing patient-centered care, and evaluating the outcomes. Student feedback has shown that these Nursing Process Application charts are a significant component of planning and implementing nursing care plans.

The QSEN competencies related to patient-centered care, teamwork and collaboration, evidence-based practice, and patient safety are incorporated throughout the features and Nursing Practice Application charts.

No pharmacology text is complete unless it contains a method of self-assessment by which students may gauge their progress. Pharmacology for Nurses: A Pathophysiologic Approach contains an end-of-chapter review of the major concepts. NCLEX-RN®-style questions, a Patient-Focused Case Study with critical thinking questions, and an additional set of Critical Thinking questions allow students to check their retention of chapter material. References and Selected Bibliography sources are also located at the end of each chapter.
Preface

Nursing Practice Application
Pharmacotherapy with Adrenergic Drugs

ASSESSMENT
Baseline assessment prior to administration:
• Obtain a complete health history and drug history, including allergies, current prescription and over-the-counter (OTC) drugs, and herbal preparations. Be alert to possible drug interactions.
• Evaluate appropriate laboratory findings, such as liver or kidney function studies.
• Obtain baseline vital signs, weight, and urinary and cardiac output as appropriate.
• Assess the nasal mucosa for exudation or bleeding prior to beginning therapy for nasal congestion.
• Assess the patient’s ability to receive and understand instruction. Include the family and caregivers as needed.

Assessment throughout administration:
• Assess for desired therapeutic effects (e.g., increased ease of breathing, blood pressure [BP] within normal range, nasal congestion improved).
• Continue frequent and careful monitoring of vital signs and urinary and cardiac output as appropriate, especially if IV administration is used.
• Assess for and promptly report adverse effects: tachycardia, hypertension, dysrhythmias, tremors, dizziness, headache, and decreased urinary output. Immediately report severe hypertension, seizures, and angina, which may signal drug toxicity.

IMPLEMENTATION

Interventions and (Rationales) Patient-Centered Care

Ensuring therapeutic effects:
• Continue frequent assessments for therapeutic effects. (Pulse, BP, and respiratory rate should be within normal limits or within the parameters set by the healthcare provider. Nasal congestion should be decreased; reddened, irritated sclera should be improved.)
• Teach the patient to report increasing dyspnea despite medication therapy and to not take more than the prescribed dose unless instructed otherwise by the healthcare provider.

Minimizing adverse effects:
• Monitor for signs of excessive autonomic nervous system stimulation and notify the healthcare provider if the BP or pulse exceeds established parameters. Continue frequent cardiac monitoring (e.g., electrocardiogram [ECG], cardiac output) and urine output if IV adrenergics are given. (Adrenergic drugs stimulate the heart rate and raise BP, and require frequent monitoring. Lifespan: The older adult may be at greater risk due to previously existing cardiovascular disease. Diverse Patients: Research suggests African Americans may experience an impaired [diminished] vascular response to isoproterenol, and vital signs should be monitored frequently during administration.)
• Teach the patient not to use nasal spray longer than 3–5 days without consulting the healthcare provider. OTC saline nasal sprays may provide comfort if mucosa is dry and irritated. Increasing oral fluid intake may also help with hydration. Lifespan: Teach the caregiver that adrenergic nasal sprays and other decongestants are not recommended in children and should be used only under a provider’s supervision.

• Monitor oral and nasal mucosa and appropriate laboratory work. (Adrenergic stimulation may increase blood glucose.)
• Teach the patient with diabetes to monitor his or her blood glucose more frequently and to notify the healthcare provider if a consistent increase is noted. A change in antidiabetes medications or dosing may be required if glucose remains elevated.

• Ensure that the patient is able to use the inhaler properly. (Using time during nursing care helps to optimize and reinforce key teaching areas.)
• Instruct the patient to keep the drug within reach and to notify the healthcare provider if he or she has taken the manufactured dose. The provider should be notified if irritation or sensitivity occurs beyond 12 hours after the drug has been discontinued. Soft contact lens users should check with the provider before using, as some solutions may stain lenses. Lifespan & Safety: Assist the older adult with ambulation if blurred vision or light sensitivity occurs, to prevent falls.

Patient understanding of drug therapy:
• Use opportunities during administration of medications and during assessments to provide patient education. (Using time during nursing care helps to optimize and reinforce key teaching areas.)
• The patient or caregiver should be able to state the reason for the drug, dose and scheduling, adverse effects to observe for and when to report; equipment needed as appropriate and how to use that equipment; and the required length of medication therapy needed with any special instructions regarding renewing or continuing the prescription as appropriate.

Patient self-administration of drug therapy:
• When administering medications, instruct the patient or caregiver in proper self-administration of an inhaler, epinephrine auto-injector kit, nasal spray, or ophthalmic drops. (Using time during nurse administration of these drugs helps to reinforce teaching.)
• Instruct the patient in proper administration techniques, followed by teach-back. Inhalation forms should only be dispensed when the patient is upright to properly aerosolize the drug and prevent overdosage from excessively large droplets. Lifespan: Teach the patient to use all equipment obtained. 911 and the healthcare provider should be called immediately after use.

See Table 13.3 for a list of drugs to which these nursing actions apply.
Chapter Review

KEY Concepts

The numbered key concepts provide a succinct summary of the important points from the corresponding numbered sections within the chapter. If any of these points are not clear, refer to the numbered section within the chapter.

1. Norepinephrine is the primary neurotransmitter released at adrenergic receptors, which are divided into alpha and beta subtypes. Drugs can alter neural transmission across a synapse by preventing the synthesis, storage, or release of the neurotransmitter, or preventing the destruction of the neurotransmitter.

2. Amphetamines are used primarily for treatment of Parkinson’s disease and attention-deficit hyperactivity disorder.

3. Epinephrine is used for treatment of anaphylaxis and shock, as well as for asthma. It is used in the treatment of certain cardiac conditions.

REVIEW Questions

1. Following administration of phenylephrine (Neo-Synephrine), the nurse would expect the medication to cause which of the following effects?
   - Increased heart rate
   - Constriction of blood vessels
   - Bronchodilation

2. The healthcare provider prescribes epinephrine (Adrenalin) for a patient who was stung by several wasps 30 minutes ago and is experiencing an allergic reaction. The nurse knows that the primary purpose of this medication for this patient is to:
   - Reduce swelling
   - Increase heart rate
   - Decrease blood pressure

3. A 24-year-old patient is evaluated for seasonal allergies to ragweed. The provider recommends taking the medication for high blood pressure and my blood pressure is 140/90 mmHg.
   - The medication is likely to be:
     - Propranolol (Inderal)
     - Amlodipine (Norvasc)
     - Lisinopril (Pravachol)

4. When taking the medication, the patient should be:
   - Take the medication after meals.
   - Drink a full glass of water before rising.
   - Avoid sleeping in a prone position.

IMPLEMENTATION

Adrenergic Drugs Affecting the Autonomic Nervous System

1. Increased bronchial secretions, hypotension, and nausea, vomiting, and hypotension

2. Synephrine (Neo-Synephrine) provide? What adverse effects should the patient be warned about?

3. Synephrine), the nurse would assess for which therapeutic effects will the phenylephrine (Neo-Synephrine) most likely provide? What adverse effects should the patient be warned about?

4. The mechanism of action associated with propranolol (Inderal) is to:
   - Block beta-receptors
   - Block alpha-receptors
   - Stimulate alpha-receptors

REFERENCES


SELECTED BIBLIOGRAPHY


Acknowledgments

When authoring a textbook like this, many dedicated and talented professionals are needed to bring the vision to reality. Pamela Fuller, Executive Portfolio Manager, and Michael Giacobbe, Program Manager, are responsible for guiding the many details in the development and production of the sixth edition. Our Development Editor, Teri Zak, provided leadership, motivation, and expert guidance to keep everyone on track and on schedule. Her steadfast attention to detail and her editorial expertise enabled an excellent outcome for this edition.

Although difficult and challenging, the study of pharmacology is truly a fascinating lifelong journey. We hope we have succeeded in writing a textbook that makes that study easier and more understandable so that nursing students will be able to provide safe, effective nursing care to patients who are undergoing drug therapy. We hope students and faculty will share with us their experiences using this textbook and all its resources.
## Contents

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>About the Authors</strong></td>
</tr>
<tr>
<td><strong>Thank You</strong></td>
</tr>
<tr>
<td><strong>Preface</strong></td>
</tr>
</tbody>
</table>

### Unit 1

#### Core Concepts in Pharmacology

<table>
<thead>
<tr>
<th>1</th>
<th>Introduction to Pharmacology</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>History of Pharmacology</td>
<td>3</td>
</tr>
<tr>
<td>1.2</td>
<td>Pharmacology: The Study of Medicines</td>
<td>3</td>
</tr>
<tr>
<td>1.3</td>
<td>Pharmacology and Therapeutics</td>
<td>4</td>
</tr>
<tr>
<td>1.4</td>
<td>Classification of Therapeutic Agents as Drugs, Biologics, Biosimilars, and Complementary and Alternative Medicine Therapies</td>
<td>4</td>
</tr>
<tr>
<td>1.5</td>
<td>Therapeutic and Pharmacologic Classification of Drugs</td>
<td>4</td>
</tr>
<tr>
<td>1.6</td>
<td>Chemical, Generic, and Trade Names for Drugs</td>
<td>5</td>
</tr>
<tr>
<td>1.7</td>
<td>Prescription and Over-the-Counter Drugs</td>
<td>6</td>
</tr>
<tr>
<td>1.8</td>
<td>Differences Between Trade-Name Drugs and Their Generic Equivalents</td>
<td>6</td>
</tr>
<tr>
<td>1.9</td>
<td>Decisions Relative to Proper Drug Choices</td>
<td>8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2</th>
<th>Drug Approval and Regulation</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>Drug Regulations and Standards</td>
<td>11</td>
</tr>
<tr>
<td>2.2</td>
<td>The Role of the Food and Drug Administration</td>
<td>12</td>
</tr>
<tr>
<td>2.3</td>
<td>Phases of Approval for Therapeutic and Biologic Drugs</td>
<td>13</td>
</tr>
<tr>
<td>2.4</td>
<td>Changes to the Drug Approval Process</td>
<td>15</td>
</tr>
<tr>
<td>2.5</td>
<td>Prescriptive Authority for Nurses</td>
<td>15</td>
</tr>
<tr>
<td>2.6</td>
<td>Controlled Substances, Drug Schedules, and Teratogenic Risks</td>
<td>16</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3</th>
<th>Principles of Drug Administration</th>
<th>19</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1</td>
<td>Medication Knowledge and Understanding</td>
<td>20</td>
</tr>
<tr>
<td>3.2</td>
<td>The Rights of Drug Administration</td>
<td>21</td>
</tr>
<tr>
<td>3.3</td>
<td>Patient Adherence and Successful Pharmacotherapy</td>
<td>21</td>
</tr>
<tr>
<td>3.4</td>
<td>Drug Orders and Time Schedules</td>
<td>22</td>
</tr>
<tr>
<td>3.5</td>
<td>Systems of Measurement</td>
<td>23</td>
</tr>
<tr>
<td>3.6</td>
<td>Enteral Drug Administration</td>
<td>24</td>
</tr>
<tr>
<td>3.7</td>
<td>Topical Drug Administration</td>
<td>26</td>
</tr>
<tr>
<td>3.8</td>
<td>Parenteral Drug Administration</td>
<td>30</td>
</tr>
<tr>
<td>4</td>
<td>Pharmacokinetics</td>
<td>37</td>
</tr>
<tr>
<td>4.1</td>
<td>Pharmacokinetics: How the Body Handles Medications</td>
<td>38</td>
</tr>
<tr>
<td>4.2</td>
<td>The Passage of Drugs Through Plasma Membranes</td>
<td>38</td>
</tr>
<tr>
<td>4.3</td>
<td>Absorption of Medications</td>
<td>38</td>
</tr>
<tr>
<td>4.4</td>
<td>Distribution of Medications</td>
<td>40</td>
</tr>
<tr>
<td>4.5</td>
<td>Metabolism of Medications</td>
<td>41</td>
</tr>
<tr>
<td>4.6</td>
<td>Excretion of Medications</td>
<td>42</td>
</tr>
<tr>
<td>4.7</td>
<td>Drug Plasma Concentration and Therapeutic Response</td>
<td>43</td>
</tr>
<tr>
<td>4.8</td>
<td>Onset, Peak Levels, and Duration of Drug Action</td>
<td>45</td>
</tr>
<tr>
<td>4.9</td>
<td>Loading Doses and Maintenance Doses</td>
<td>45</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5</th>
<th>Pharmacodynamics</th>
<th>48</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1</td>
<td>Pharmacodynamics and Interpatient Variability</td>
<td>49</td>
</tr>
<tr>
<td>5.2</td>
<td>Therapeutic Index and Drug Safety</td>
<td>49</td>
</tr>
<tr>
<td>5.3</td>
<td>The Graded Dose—Response Relationship and Therapeutic Response</td>
<td>50</td>
</tr>
<tr>
<td>5.4</td>
<td>Potency and Efficacy</td>
<td>51</td>
</tr>
<tr>
<td>5.5</td>
<td>Cellular Receptors and Drug Action</td>
<td>51</td>
</tr>
<tr>
<td>5.6</td>
<td>Types of Drug—Receptor Interactions</td>
<td>53</td>
</tr>
<tr>
<td>5.7</td>
<td>Pharmacology of the Future: Customizing Drug Therapy</td>
<td>53</td>
</tr>
</tbody>
</table>

### Unit 2

#### Pharmacology and the Nurse–Patient Relationship

<table>
<thead>
<tr>
<th>6</th>
<th>The Nursing Process in Pharmacology</th>
<th>58</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1</td>
<td>Overview of the Nursing Process</td>
<td>59</td>
</tr>
<tr>
<td>6.2</td>
<td>Assessment of the Patient</td>
<td>60</td>
</tr>
</tbody>
</table>
6.3 Nursing Diagnoses 61
6.4 Planning: Establishing Goals and Outcomes 62
6.5 Implementing Specific Nursing Actions 63
6.6 Evaluating the Effects of Medications 64

7 Medication Errors and Risk Reduction 67
7.1 Defining Medication Errors 68
7.2 Factors Contributing to Medication Errors 68
7.3 The Impact of Medication Errors 68
7.4 Reporting and Documenting Medication Errors 70
7.5 Strategies for Reducing Medication Errors 71
7.6 Medication Reconciliation 72
7.7 Effective Patient Teaching for Medication Usage 73
7.8 How the Healthcare Industry Is Increasing Medication Safety 73

8 Drug Administration Throughout the Lifespan 77
8.1 Pharmacotherapy Across the Lifespan 78
8.2 Pharmacotherapy of the Pregnant Patient 78
8.3 Pharmacotherapy of the Lactating Patient 80
8.4 Pharmacotherapy of Infants 82
8.5 Pharmacotherapy of Toddlers 82
8.6 Pharmacotherapy of Preschoolers and School-Age Children 83
8.7 Pharmacotherapy of Adolescents 84
8.8 Pharmacotherapy of Young and Middle-Aged Adults 85
8.9 Pharmacotherapy of Older Adults 85

9 Individual Variations in Drug Response 89
9.1 The Concept of Holistic Pharmacotherapy 90
9.2 Psychosocial Influences on Pharmacotherapy 90
9.3 Cultural and Ethnic Influences on Pharmacotherapy 91
9.4 Community and Environmental Influences on Pharmacotherapy 92
9.5 Gender Influences on Pharmacotherapy 92
9.6 Genetic Influences on Pharmacotherapy 93

10 The Role of Complementary and Alternative Therapies in Pharmacology 97
10.1 Complementary and Alternative Medicine 98
10.2 Brief History of Herbal Therapies 99
10.3 Herbal Product Formulations 100
10.4 Regulation of Herbal Products and Dietary Supplements 101
10.5 The Pharmacologic Actions and Safety of Herbal Products 102
10.6 Specialty Supplements 103
10.7 Patient Teaching Regarding CAM 104

11 Emergency Preparedness and Poisonings 107
11.1 The Nature of Worldwide Epidemics and Bioterrorist Threats 108
11.2 Role of the Nurse in Emergency Preparedness 109
11.3 Strategic National Stockpile 110
11.4 Anthrax 111
11.5 Viruses 112
11.6 Toxic Chemicals 113
11.7 Ionizing Radiation 113
11.8 Management of Poisonings 114

Unit 3

The Nervous System 119

12 Cholinergic Drugs Affecting the Autonomic Nervous System 120
12.1 Overview of the Nervous System 121
12.2 Sympathetic and Parasympathetic Divisions 122
12.3 Structure and Function of Autonomic Synapses 123
12.4 Acetylcholine and Cholinergic Transmission 123
12.5 Classification and Naming of Drugs Affecting the Parasympathetic Nervous System 124
12.6 Clinical Applications of Cholinergic Drugs 126
12.7 Clinical Applications of Anticholinergics 127

Nursing Practice Application Pharmacotherapy with Cholinergic Drugs 129

Nursing Practice Application Pharmacotherapy with Anticholinergic Drugs 132

13 Adrenergic Drugs Affecting the Autonomic Nervous System 137
13.1 Norepinephrine and Adrenergic Transmission 138
13.2 Clinical Applications of Adrenergic Drugs 140

Nursing Practice Application Pharmacotherapy with Adrenergic Drugs 143
13.3 Clinical Applications of Adrenergic-Blocking Drugs 144
   Nursing Practice Application  Pharmacotherapy with Adrenergic-Blocking Drugs 146

14 Drugs for Anxiety and Insomnia 151
   14.1 Types of Anxiety Disorders 152
   14.2 Specific Regions of the Brain Responsible for Anxiety and Wakefulness 152
   14.3 Anxiety Management Through Pharmacologic and Nonpharmacologic Strategies 154
   14.4 Insomnia and Its Link to Anxiety 154
   14.5 Use of the Electroencephalogram to Diagnose Sleep Disorders 155
   14.6 Treating Anxiety and Insomnia with CNS Drugs 156
   14.7 Treating Anxiety with Antidepressants 156
   14.8 Treating Anxiety with Benzodiazepines 156
   14.9 Use of Barbiturates as Sedatives 161
   Nursing Practice Application  Pharmacotherapy for Anxiety or Sleep Disorders 163

15 Drugs for Seizures 168
   15.1 Causes of Seizures 169
   15.2 Types of Seizures 170
   15.3 General Concepts of Antiseizure Pharmacotherapy 170
   15.4 Mechanisms of Action of Antiseizure Drugs 172
   15.5 Treating Seizures with Antiepileptics 174
   15.6 Treating Seizures with Anticonvulsants 176
   15.7 Treating Seizures with Hydantoins and Related Drugs 176
   15.8 Treating Seizures with Succinimides 179
   Nursing Practice Application  Pharmacotherapy with Antiseizure Drugs 180

16 Drugs for Emotional, Mood, and Behavioral Disorders 186
   16.1 Characteristics and Forms of Depression 187
   16.2 Assessment and Nonpharmacologic Treatment of Depression 187
   16.3 Mechanism of Action of Antidepressants 188
   16.4 Treating Depression with Selective Serotonin Reuptake Inhibitors 191
   16.5 Treating Depression with Atypical Antidepressants 192
   16.6 Treating Depression with Tricyclic Antidepressants 193
   16.7 Treating Depression with MAOIs 194
   16.8 Characteristics of Bipolar Disorder 195
   16.9 Pharmacotherapy of Bipolar Disorder 195
   Nursing Practice Application  Pharmacotherapy for Mood Disorders 197

17 Drugs for Psychoses 208
   17.1 The Nature of Psychoses 209
   17.2 Schizophrenia 209
   17.3 Pharmacologic Management of Psychoses 210
   17.4 Treating Psychoses with Phenothiazines 211
   17.5 Treating Psychoses with Nonphenothiazines 214
   17.6 Treating Psychoses with Second-Generation (Atypical) Antipsychotics 215
   Nursing Practice Application  Pharmacotherapy with Antipsychotic Drugs 217
   17.7 Treating Psychoses with Dopamine-Serotonin System Stabilizers 219

18 Drugs for the Control of Pain 223
   18.1 Assessment and Classification of Pain 224
   18.2 The Neural Mechanisms of Pain 224
   18.3 Complementary and Alternative Therapies for Pain Management 226
   18.4 Classification of Opioids 227
   18.5 Pharmacotherapy with Opioid Agonists 227
   18.6 Pharmacotherapy with Opioid Antagonists 230
   OPIOIDS WITH MIXED AGONIST–ANTAGONIST ACTIVITY 231
   18.7 Treatment for Opioid Dependence 231
   Nursing Practice Application  Pharmacotherapy for Pain 232
   18.8 Pharmacotherapy with NSAIDs 234
   ASPIRIN, IBUPROFEN, AND COX-2 INHIBITORS 234
   CENTRALLY ACTING DRUGS 234
   18.9 Adjuvant Analgesics 236
   18.10 Classification of Headaches 237
   DRUG THERAPY FOR TENSION HEADACHES 238
   ANTIMIGRAINE DRUGS 238
   18.11 Drug Therapy for Migraines 238
   Nursing Practice Application  Pharmacotherapy for Migraines 240

19 Drugs for Local and General Anesthesia 245
   19.1 Regional Loss of Sensation Using Local Anesthesia 246
   LOCAL ANESTHETICS 246
   19.2 Mechanism of Action of Local Anesthetics 246
   19.3 Classification of Local Anesthetics 248
Contents xvii

22.3 Physical and Psychologic Dependence 293
22.4 Withdrawal Syndrome 294
22.5 Tolerance 295
22.6 Central Nervous System Depressants 295
SEDATIVES AND SEDATIVE–HYPNOTICS 295
OPIOIDS 296
ETHYL ALCOHOL 296
22.7 Cannabinoids 298
MARIJUANA 298
22.8 Hallucinogens 298
LSD 298
RECREATIONAL AND CLUB DRUGS 299
22.9 Central Nervous System Stimulants 299
AMPHETAMINES AND METHYLPHENIDATE 299
COCAINE 300
CAFFEINE 300
22.10 Nicotine 300
TOBACCO USE AND NICOTINE PRODUCTS 300
22.11 The Nurse’s Role in Substance Use 301

Unit 4

The Cardiovascular and Urinary Systems 305

23 Drugs for Lipid Disorders 306
23.1 Types of Lipids 307
23.2 Lipoproteins 307
23.3 LDL and Cardiovascular Disease 308
23.4 Controlling Lipid Levels Through Lifestyle Changes 309
23.5 Pharmacotherapy with Statins 310
23.6 Bile Acid Sequestrants for Reducing Cholesterol and LDL Levels 313
23.7 Pharmacotherapy with Niacin 314
23.8 Pharmacotherapy with Fibric Acid Drugs 315
23.9 Pharmacotherapy with Miscellaneous Drugs for Dyslipidemias 316
Nursing Practice Application Lipid-Lowering Pharmacotherapy 316

24 Diuretic Therapy and Drugs for Kidney Failure 321
24.1 Functions of the Kidneys 322
24.2 Renal Reabsorption and Secretion 322
24.3 Diagnosis and Pharmacotherapy of Kidney Failure 323
24.4 Mechanisms of Action of Diuretics 324
24.5 Pharmacotherapy with Loop Diuretics 325
24.6 Pharmacotherapy with Thiazide Diuretics 327
24.7 Pharmacotherapy with Potassium-Sparing Diuretics 329
27.2 Treatment of Heart Failure with Angiotensin-Converting Inhibitors and Angiotensin Receptor Blockers 375
27.3 Treatment of Heart Failure with Diuretics 377
27.4 Treatment of Heart Failure with Beta-Adrenergic Blockers (Antagonists) 378
27.5 Treatment of Heart Failure with Cardiac Glycosides 378
27.6 Treatment of Heart Failure with Vasodilators 380
27.7 Treatment of Heart Failure with Phosphodiesterase Inhibitors 381

Nursing Practice Application Pharmacotherapy for Heart Failure 382

28 Drugs for Angina Pectoris and Myocardial Infarction 387
28.1 Pathogenesis of Coronary Artery Disease 388
28.2 Pathogenesis of Angina Pectoris 388
28.3 Nonpharmacologic Management of Angina 389
28.4 Treating Angina with Organic Nitrates 390
28.5 Treating Angina with Beta-Adrenergic Blockers 392
28.6 Treating Angina with Calcium Channel Blockers 392

Nursing Practice Application Pharmacotherapy with Organic Nitrates 393
28.7 Diagnosis of Acute Coronary Syndrome 396
28.8 Treating Myocardial Infarction with Thrombolytics 397
28.9 Adjunct Drugs for Symptoms and Complications of Acute Myocardial Infarction 399
ANTIPATELET AND ANTIICOAGULANT DRUGS 399
NITRATES 400
BETA-ADRENERGIC BLOCKERS 400
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 400
PAIN MANAGEMENT 400

29 Drugs for Shock 404
29.1 Characteristics of Shock 405
29.2 Causes of Shock 405
29.3 Treatment Priorities for a Patient in Shock 406
29.4 Treating Shock with Intravenous Fluid Therapy 407
29.5 Treating Shock with Vasoconstrictors (Vaspressors) 407
29.6 Treating Shock with Inotropic Drugs 409

Nursing Practice Application Pharmacotherapy for Shock 410
29.7 Pharmacotherapy of Anaphylaxis 412

30 Drugs for Dysrhythmias 416
30.1 Etiology and Classification of Dysrhythmias 417
30.2 Conduction Pathways in the Myocardium 417
30.3 The Electrocardiograph 418
30.4 Nonpharmacologic Treatment of Dysrhythmias 419
30.5 Phases of the Myocardial Action Potential 419
30.6 Mechanisms and Classification of Antidysrhythmic Drugs 421
30.7 Treating Dysrhythmias with Sodium Channel Blockers 421
30.8 Treating Dysrhythmias with Beta-Adrenergic Antagonists 421
30.9 Treating Dysrhythmias with Potassium Channel Blockers 423
30.10 Treating Dysrhythmias with Calcium Channel Blockers 425
30.11 Miscellaneous Drugs for Dysrhythmias 427

Nursing Practice Application Pharmacotherapy with Antidysrhythmic Drugs 427

31 Drugs for Coagulation Disorders 431
31.1 The Process of Hemostasis 432
31.2 Removal of Blood Clots 433
31.3 Alterations of Hemostasis 434
THROMBOEMBOLIC DISORDERS 434
COAGULATION DISORDERS 434
31.4 Mechanisms of Coagulation Modification 434
31.5 Pharmacotherapy with Anticoagulants 437
HEPARIN, LOW-MOLECULAR-WEIGHT HEPARINS, AND RELATED DRUGS 437
VITAMIN K ANTAGONISTS 437
DIRECT THROMBIN INHIBITORS 437
FACTOR XA INHIBITORS 439
31.6 Pharmacotherapy with Antiplatelet Drugs 440
Nursing Practice Application Pharmacotherapy with Antiplatelet Drugs 441
31.7 Pharmacotherapy with Thrombolytics 443
Nursing Practice Application Pharmacotherapy with Thrombolytics 444
31.8 Pharmacotherapy with Hemostatics 446
31.9 Pharmacotherapy of Hemophilia 447

32 Drugs for Hematopoietic Disorders 451
32.1 Hematopoiesis 452
32.2 Pharmacotherapy with Erythropoiesis-Stimulating Drugs 454
32.3 Pharmacotherapy with Colony-Stimulating Factors 454
Nursing Practice Application Pharmacotherapy with Erythropoiesis-Stimulating Drugs 455
Nursing Practice Application Pharmacotherapy with Colony-Stimulating Factors 457
32.4 Pharmacotherapy with Platelet Enhancers 459
32.5 Classification of Anemias 460
32.6 Pharmacotherapy with Vitamin B₁₂ and Folic Acid 460
32.7 Pharmacotherapy with Iron 461

Nursing Practice Application Pharmacotherapy for Anemia (Folic Acid, Vitamin B₁₂, Ferrous Sulfate) 464

Unit 5
The Immune System 469

33 Drugs for Inflammation and Fever 470
33.1 The Function of Inflammation 471
33.2 The Role of Chemical Mediators in Inflammation 471
33.3 General Strategies for Treating Inflammation 472
33.4 Treating Inflammation with NSAIDs 473
SALICYLATES 474
IBUPROFEN AND IBUPROFEN-LIKE NSAIDS 475
SELECTIVE COX-2 INHIBITORS 475
33.5 Treating Acute or Severe Inflammation with Corticosteroids 476
33.6 Treating Fever with Antipyretics 478

Nursing Practice Application Pharmacotherapy with Anti-Inflammatory and Antipyretic Drugs 479

34 Drugs for Immune System Modulation 485
34.1 Innate (Nonspecific) Body Defenses and the Immune Response 486
34.2 Humoral Immune Response and Antibodies 486
34.3 Administration of Vaccines 487
34.4 Cell-Mediated Immunity and Cytokines 490
34.5 Pharmacotherapy with Biologic Response Modifiers 491
Nursing Practice Application Pharmacotherapy with Immunostimulants 495
34.6 Immunosuppressants for Preventing Transplant Rejection and for Treating Inflammation 496
TRANSPLANTATION 496
ACUTE INFLAMMATORY DISORDERS 497
Nursing Practice Application Pharmacotherapy with Immunosuppressants 499

35 Drugs for Bacterial Infections 503
35.1 Pathogenicity and Virulence 504
35.2 Describing and Classifying Bacteria 504
35.3 Classification of Anti-Infective Drugs 505
35.4 Actions of Anti-Infective Drugs 505
35.5 Acquired Resistance 506
35.6 Selection of an Effective Antibiotic 508
35.7 Host Factors 509
HOST DEFENSES 509
LOCAL TISSUE CONDITIONS 509
Contents

ALLERGY HISTORY 509
OTHER PATIENT VARIABLES 509

35.8 Pharmacotherapy with Penicillins 510
35.9 Pharmacotherapy with Cephalosporins 512
35.10 Pharmacotherapy with Tetracyclines 514
35.11 Pharmacotherapy with Macrolides 514
35.12 Pharmacotherapy with Aminoglycosides 516
35.13 Pharmacotherapy with Fluoroquinolones 518
35.14 Pharmacotherapy with Sulfonamides and Urinary Antiseptics 519
35.15 Pharmacotherapy with Carbapenems and Miscellaneous Antibacterials 521

Nursing Practice Application Pharmacotherapy with Antibacterial Drugs 524

36 Drugs for Tubercular, Fungal, Protozoan, and Helminthic Infections 530

36.1 Pharmacotherapy of Tuberculosis 532
36.2 Characteristics of Fungi 532

Nursing Practice Application Pharmacotherapy with Antitubercular Drugs 533
36.3 Classification of Mycoses 535
36.4 Mechanism of Action of Antifungal Drugs 536
36.5 Pharmacotherapy of Systemic Fungal Diseases 536
36.6 Pharmacotherapy with the Azole Antifungals 537
SYSTEMIC AZOLES 539
TOPICAL AZOLES 539
36.7 Pharmacotherapy of Superficial Fungal Infections 539

Nursing Practice Application Pharmacotherapy with Antifungal Drugs 541
36.8 Pharmacotherapy of Malaria 543
36.9 Pharmacotherapy of Nonmalarial Protozoan Infections 544
36.10 Pharmacotherapy of Helminthic Infections 546

37 Drugs for Viral Infections 551

37.1 Characteristics of Viruses 552
37.2 Replication of HIV 553
37.3 General Principles of HIV Pharmacotherapy 554
37.4 Classification of Drugs for HIV and AIDS 555
37.5 Pharmacotherapy with Reverse Transcriptase Inhibitors 557
37.6 Pharmacotherapy with Protease Inhibitors 558
37.7 Pharmacotherapy with Integratease Strand Inhibitors and Entry Inhibitors 559

Nursing Practice Application Pharmacotherapy for HIV and AIDS 561
37.8 Prevention of Perinatal Transmission of HIV 563
37.9 Postexposure Prophylaxis of HIV Infection Following Occupational Exposure 564
37.10 Pharmacotherapy of Herpesvirus Infections 565
37.11 Pharmacotherapy of Influenza 566
37.12 Pharmacotherapy of Viral Hepatitis 567
HEPATITIS A 567
HEPATITIS B 567
HEPATITIS C AND OTHER HEPATITIS VIRUSES 568

Nursing Practice Application Pharmacotherapy for Non-HIV Viral Infections 569

38 Drugs for Neoplasia 574

38.1 Characteristics of Cancer 575
38.2 Causes of Cancer 575
38.3 Goals of Cancer Chemotherapy: Cure, Control, and Palliation 576
38.4 Growth Fraction and Success of Chemotherapy 577
38.5 Achieving a Total Cancer Cure 578
38.6 Special Chemotherapy Protocols and Strategies 578
COMBINATION CHEMOTHERAPY 578
DOsing SCHEDULES 579
38.7 Toxicity of Antineoplastic Drugs 579
38.8 Pharmacotherapy with Alkylating Agents 580
38.9 Pharmacotherapy with Antimetabolites 581
FOLIC ACID ANALOGS 581
PURINE AND PYRIMIDINE ANALOGS 583
38.10 Pharmacotherapy with Antitumor Antibiotics 583
38.11 Pharmacotherapy with Natural Products 585
38.12 Pharmacotherapy with Hormones and Hormone Antagonists 585
CORTICOSTEROIDS (GLUCOCORTICOIDS) 587
GONADAL HORMONES 587
ESTROGEN ANTAGONISTS (ANTIESTROGENS) 587
ANDROGEN ANTAGONISTS (ANTIANDROGENS) 588
38.13 Pharmacotherapy with Biologic Response Modifiers and Targeted Therapies 591
38.14 Miscellaneous Antineoplastics 591

Nursing Practice Application Pharmacotherapy for Cancer 594

Unit 6

The Respiratory System 599

39 Drugs for Allergic Rhinitis and the Common Cold 600

39.1 Physiology of the Upper Respiratory Tract 601
39.2 Pharmacotherapy of Allergic Rhinitis 602
39.3 Pharmacology of Allergic Rhinitis with H1-Receptor Antagonists and Mast Cell Stabilizers 603
39.4 Pharmacotherapy of Allergic Rhinitis with Intranasal Corticosteroids 605
39.5 Pharmacotherapy of Nasal Congestion with Decongestants 606
COMMON COLD 608
40 Drugs for Asthma and Other Pulmonary Disorders 616

40.1 Physiology of the Lower Respiratory Tract 617
40.2 Bronchiolar Smooth Muscle 617
40.3 Administration of Pulmonary Drugs via Inhalation 618
40.4 Pathophysiology of Asthma 618
40.5 Treating Acute Asthma with Beta-Adrenergic Agonists 620
40.6 Treating Chronic Asthma with Anticholinergics 623
40.7 Treating Chronic Asthma with Methylxanthines 624
40.8 Prophylaxis of Asthma with Corticosteroids 624
40.9 Prophylaxis of Asthma with Leukotriene Modifiers 626
40.10 Prophylaxis of Asthma with Mast Cell Stabilizers 626
40.11 Monoclonal Antibodies for Asthma Prophylaxis 627
40.12 Pharmacotherapy of COPD 627

Nursing Practice Application Pharmacotherapy for Asthma and COPD 628

43 Drugs for Nutritional Disorders 668

43.1 Role of Vitamins in Maintaining Health 669
43.2 Classification of Vitamins 669
43.3 Recommended Dietary Allowances 669
43.4 Indications for Vitamin Pharmacotherapy 669
43.5 Pharmacotherapy with Lipid-Soluble Vitamins 671
43.6 Pharmacotherapy with Water-Soluble Vitamins 672
43.7 Indications for Mineral Pharmacotherapy 674
43.8 Pharmacotherapy with Minerals 676

Nursing Practice Application Pharmacotherapy with Vitamins and Minerals 678

43.9 Etiology of Undernutrition 679
43.10 Enteral Nutrition 680
43.11 Parenteral Nutrition 680

Nursing Practice Application Enteral and Parenteral Nutrition Therapy 681

43.12 Etiology of Obesity 683
43.13 Pharmacotherapy of Obesity 684

Unit 8

The Endocrine System 689

44 Drugs for Pituitary, Thyroid, and Adrenal Disorders 690

44.1 The Endocrine System and Homeostasis 691
44.2 Indications for Hormone Pharmacotherapy 691
44.3 The Endocrine Structures of the Brain 692
44.4 Pharmacotherapy with Hypothalamic and Pituitary Hormones 693

GROWTH HORMONE 694

ANTIDIURETIC HORMONE 695

Nursing Practice Application Pharmacotherapy with Hypothalamic and Pituitary Hormones 696
Contents

44.5 Normal Function of the Thyroid Gland  697
44.6 Pharmacotherapy of Hypothyroidism  698
44.7 Pharmacotherapy of Hyperthyroidism  699
  Nursing Practice Application  Pharmacotherapy for Thyroid Disorders  701
44.8 Normal Function of the Adrenal Glands  703
  GONADOCORTICOIDS  703
  MINERALOCORTICOIDS  703
  GLUCOCORTICOIDS  703
44.9 Regulation of Corticosteroid Secretion  703
44.10 Pharmacotherapy with Corticosteroids  704
44.11 Pharmacotherapy of Cushing’s Syndrome  706
  Nursing Practice Application  Pharmacotherapy with Systemic Corticosteroids  708

45 Drugs for Diabetes Mellitus  712
45.1 Regulation of Blood Glucose Levels  713
45.2 Etiology and Characteristics of Type 1 Diabetes Mellitus  713
45.3 Pharmacotherapy for Type 1 Diabetes Mellitus  715
  INSULIN ADJUNCT  717
  Nursing Practice Application  Pharmacotherapy with Insulin  718
45.4 Etiology and Characteristics of Type 2 Diabetes Mellitus  720
45.5 Pharmacotherapy for Type 2 Diabetes Mellitus  721
  SULFONYLUREAS  721
  BIGUANIDES  723
  ALPHA-GLUCOSIDASE INHIBITORS  723
  THIAZOLIDINEDIONES  723
  MEGLITINIDES  723
  INCRETIN THERAPIES AND MISCELLANEOUS DRUGS  723
  Nursing Practice Application  Pharmacotherapy for Type 2 Diabetes  725

46 Drugs for Disorders and Conditions of the Female Reproductive System  729
46.1 Hypothalamic and Pituitary Regulation of Female Reproductive Function  730
46.2 Ovarian Control of Female Reproductive Function  730
46.3 Estrogens and Progestins as Oral Contraceptives  731
  Nursing Practice Application  Pharmacotherapy with Hormonal Contraceptives  736
46.4 Drugs for Emergency Contraception and Termination of Early Pregnancy  737
46.5 Hormone Replacement Therapy  739
46.6 Pharmacotherapy with Progestins  741
46.7 Pharmacologic Management of Uterine Contractions  742
  Nursing Practice Application  Pharmacotherapy with Oxytocin  745
46.8 Pharmacotherapy of Female Fertility  747
46.9 Pharmacotherapy of Female Hypoactive Sexual Desire Disorder  748

47 Drugs for Disorders and Conditions of the Male Reproductive System  751
47.1 Hypothalamic and Pituitary Regulation of Male Reproductive Function  752
47.2 Pharmacotherapy with Androgens  752
  Nursing Practice Application  Pharmacotherapy with Androgens  755
47.3 Pharmacotherapy of Male Infertility  756
47.4 Pharmacotherapy of Erectile Dysfunction  757
47.5 Pharmacotherapy of Benign Prostatic Hyperplasia  759
  Nursing Practice Application  Pharmacotherapy for Benign Prostatic Hyperplasia  762

Unit 9

The Integumentary System, Eyes, and Ears  767

48 Drugs for Bone and Joint Disorders  768
48.1 Role of Calcium and Vitamin D in Bone Homeostasis  769
48.2 Pharmacotherapy of Hypocalcemia  771
48.3 Pathophysiology of Metabolic Bone Diseases  771
48.4 Pharmacotherapy of Metabolic Bone Diseases  774
  VITAMIN D THERAPY  774
  BISPHONATES  774
  SELECTIVE ESTROGEN RECEPTOR MODULATORS  776
  OTHER DRUGS FOR METABOLIC BONE DISEASE  777
  Nursing Practice Application  Pharmacotherapy for Osteoporosis  778
48.5 Pharmacotherapy of Osteoarthritis  779
48.6 Pharmacotherapy of Rheumatoid Arthritis  781
48.7 Pharmacotherapy of Gout and Hyperuricemia  782
  Nursing Practice Application  Pharmacotherapy for Rheumatoid Arthritis and Osteoarthritis  783
  TREATMENT OF ACUTE GOUT  785
  TREATMENT OF CHRONIC GOUT AND PROPHYLAXIS  786
  Nursing Practice Application  Pharmacotherapy for Gout  787

49 Drugs for Skin Disorders  792
49.1 Structure and Function of the Skin  793
  EPIDERMIS  793
  DERMIS  794
  SUBCUTANEOUS TISSUE  794
49.2 Classification of Skin Disorders 794
49.3 Pharmacotherapy of Bacterial, Fungal, and Viral Skin Infections 795
49.4 Pharmacotherapy with Scabicides and Pediculicides 796
   Nursing Practice Application Pharmacotherapy for Lice or Mite Infestation 797
49.5 Pharmacotherapy of Acne 798
49.6 Pharmacotherapy of Rosacea 799
   Nursing Practice Application Pharmacotherapy for Acne and Related Skin Conditions 801
49.7 Pharmacotherapy of Dermatitis 802
49.8 Pharmacotherapy of Psoriasis 804
   TOPICAL THERAPIES 804
   SYSTEMIC THERAPIES 805
   NONPHARMACOLOGIC THERAPIES 805
49.9 Pharmacotherapy of Sunburn and Minor Skin Irritation 807

50 Drugs for Eye and Ear Disorders 810
50.1 Anatomy of the Eye 811
50.2 Types of Glaucoma 812
50.3 General Principles of Glaucoma
   Pharmacotherapy 813
50.4 Pharmacotherapy of Glaucoma 813
   PROSTAGLANDIN ANALOGS 813
   AUTONOMIC DRUGS 815
   CARBONIC ANHYDRASE INHIBITORS AND MISCELLANEOUS DRUGS 816
   OSMOTIC DIURETICS 816
50.5 Pharmacotherapy for Eye Exams and Minor Eye Conditions 816
   Nursing Practice Application Pharmacotherapy for Glaucoma 817
50.6 Pharmacotherapy with Otic Medications 819

Appendix A Answers 823
Appendix B Institute for Safe Medication Practices (ISMP):
   ISMP List of Error-Prone Abbreviations, Symbols, and Dose Designations 881
Appendix C Institute for Safe Medication Practices (ISMP)
   List of High-Alert Medications in Acute Care Settings 884
Appendix D Calculating Dosages 885
Index 887
Special Features 929